The expanded cash runway de-risks near-term execution, but the massive net loss—though largely non-recurring—warrants scrutiny. Traders should monitor upcoming IND submissions and preclinical data readouts as key value inflection points.
Price Chart
Executive Summary
Damora Therapeutics reported its full-year 2025 financial results, showing a significant increase in net loss to $209.8 million, driven by a $174.3 million charge for acquired in-process research and development. The company bolstered its cash position to $535 million as of February 28, 2026, through financings and the acquisition of a pipeline targeting mutant calreticulin-driven blood disorders, with key clinical milestones expected starting mid-2027.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $209.8 million vs. $21.4 million in 2024, primarily due to $174.3 million in acquired IPR&D costs.
- Cash and cash equivalents were $257.6 million as of December 31, 2025, and $535 million as of February 28, 2026, after two financings totaling ~$601 million.
- R&D expenses increased to $26.9 million in 2025 from $6.4 million in 2024.
- G&A expenses decreased to $9.7 million from $10.5 million year-over-year.
- Lead asset DMR-001 on track for IND/CTA submission in mid-2026, with first clinical proof-of-concept data expected from mid-2027.
- Company rebranded and now trades under ticker DMRA on Nasdaq.
Financial Impact
Cash position more than doubled to $535M, funding operations into Phase 3; however, net loss expanded nearly 10x due to one-time acquisition-related charges.
Risk Factors
- High cash burn and reliance on future financing or partnerships to sustain late-stage development.
- Clinical development risk for DMR-001 and other pipeline assets, with no near-term revenue potential.
- Forward-looking timelines (e.g., mid-2027 data) may slip, impacting investor sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259440 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $20.26 | awaiting T+20 | — | $21.26 (+4.96%) |
Sep 28, 2026 28d ago | Insider Buy | $20.75 $21.26 | ▲ +2.46% | ▲ +2.49% | $21.26 (+2.46%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $28.10 | ▼ −8.56% | ▼ −6.81% | $21.26 (−30.82%) |
Aug 10, 2026 11w ago | Press Release | $30.36 $26.27 | ▲ +13.47% | ▲ +12.41% | $21.26 (+29.97%) |
Jul 20, 2026 14w ago | 8-K | $32.99 $31.80 | ▼ −3.61% | ▼ −6.17% | $21.26 (−35.56%) |
Apr 20, 2026 27w ago | 8-K | $26.82 $24.90 | ▼ −7.16% | ▼ −12.07% | $21.26 (−20.73%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $26.82 | ▲ +16.36% | ▲ +8.94% | $21.26 (−7.77%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $26.43 | ▲ +45.70% | ▲ +36.38% | $21.26 (+17.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers